- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Analysis of long-term safety and efficacy of nucleos(t)ide analogue therapy for chronic hepatitis B during entire pregnancy
Jin Shang 1 , Huan Liu 1 , Qin Wen 1 , Rili M Ise 1 , You Tu 1 , Lang Bai 2 , Hong Tang 3
Affiliations
Affiliations
1
Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
2
Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Electronic address: [email protected].
3
Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Electronic address: [email protected].
PMID: 33722684 DOI: 10.1016/j.ijid.2021.03.023
Abstract
Objectives: There are limited data on the efficacy and long-term safety of nucleos(t)ide analogue therapy during the entire pregnancy for chronic hepatitis B women and their children.
Methods: This retrospective cohort study included totally 165 patients including 91 patients in telbivudine (LDT) group and 74 patients in tenofovir (TDF) group. The virological response and safety in women were recorded and the physical development and bone mineral density in children was followed up to five years old.
Results: The rate of virological breakthrough was 4.24% in all patients, 7.70% in LDT group and 0% in TDF group (P < 0.05). No renal injury or other obstetric adverse event in women was found. As for the physical development or bone density of children, only one child has significant low wight of age Z score (<-2) and no significant low height for age Z score or bone density was found in children, there was no significant difference between the two groups.
Conclusions: Nucleos(t)ide analogue therapy including TDF and LDT during entire pregnancy showed no effect on long-term physical development and bone development of children. Additional, TDF during their entire pregnancy showed better long-term antiviral efficacy than LDT with no evidence of renal toxicity.
Keywords: Hepatitis B virus; Nucleos(t)ide analogue; Pregnancy; Telbivudine; Tenofovir.
Copyright © 2021. Published by Elsevier Ltd. |
|